Introduction: Mesenchymal stem cells (MSCs) are immune evasive and can be transplanted to HLA-unmatched allogeneic recipients. Animal studies indicated that transplantation of MSCs improved the motor function in SCA 2 transgenic mice. This is a phase I/II clinical trial aiming to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) for the treatment of cerebellar ataxia.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Cytotherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect